Preliminary characterization of a murine model for 1-bromopropane neurotoxicity: Role of cytochrome P450
•Inhibition of P450s enabled mice to survive after 1-BP exposure at a lethal level.•Hepatotoxicity of 1-BP was significantly reduced by inhibition of P450s.•The present model is the first to show 1-BP-induced decrease in brain weight in mice.•The present model is the first to show 1-BP-induced incre...
Gespeichert in:
Veröffentlicht in: | Toxicology letters 2016-09, Vol.258, p.249-258 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 258 |
---|---|
container_issue | |
container_start_page | 249 |
container_title | Toxicology letters |
container_volume | 258 |
creator | Zong, Cai Garner, C. Edwin Huang, Chinyen Zhang, Xiao Zhang, Lingyi Chang, Jie Toyokuni, Shinya Ito, Hidenori Kato, Masashi Sakurai, Toshihiro Ichihara, Sahoko Ichihara, Gaku |
description | •Inhibition of P450s enabled mice to survive after 1-BP exposure at a lethal level.•Hepatotoxicity of 1-BP was significantly reduced by inhibition of P450s.•The present model is the first to show 1-BP-induced decrease in brain weight in mice.•The present model is the first to show 1-BP-induced increase in brain GRP78 in mice.•The present model is the first to show 1-BP-induced increase in brain Ran in mice.
Neurotoxicity of 1-bromopropane (1-BP) has been reported in both human cases and animal studies. To date, neurotoxicity of 1-BP has been induced in rats but not in mice due to the lethal hepatotoxicity of 1-BP. Oxidization by cytochromes P450 and conjugation with glutathione (GSH) are two critical metabolism pathways of 1-BP and play important roles in toxicity of 1-BP. The aim of the present study was to establish a murine model of 1-BP neurotoxicity, by reducing the hepatotoxicity of 1-BP with 1-aminobenzotriazole (1-ABT); a commonly used nonspecific P450s inhibitor. The results showed that subcutaneous or intraperitoneal injection of 1-ABT at 50mg/kg body weight BID (100mg/kg BW/day) for 3days, inhibited about 92–96% of hepatic microsomal CYP2E1 activity, but only inhibited about 62–64% of CYP2E1 activity in brain microsomes. Mice treated with 1-ABT survived even after exposure to 1200ppm 1-BP for 4 weeks and histopathological studies showed that treatment with 1-ABT protected mice from 1-BP-induced hepatic necrosis, hepatocyte degeneration, and hemorrhage. After 4-week exposure to 1-BP, the brain weight of 1-ABT(+)/1200ppm 1-BP group was decreased significantly. In 1-ABT-treated groups, expression of hippocampal Ran protein and cerebral cortical GRP78 was dose-dependently increased by exposure to 1-BP. We conclude that the control of hepatic P450 activity allows the observation of effects of 1-BP on the murine brain at a higher concentration by reduction of hepatotoxicity. The study suggests that further experiments with liver-specific control of P450 activity using gene technology might provide better murine models for 1-bromopropane-induced neurotoxicity. |
doi_str_mv | 10.1016/j.toxlet.2016.07.006 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1835579914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378427416322822</els_id><sourcerecordid>1835579914</sourcerecordid><originalsourceid>FETCH-LOGICAL-c578t-b00eaa68d06a98753e9bb45b64a3d886d34a4c9239f7294447f3c73fb91fe4323</originalsourceid><addsrcrecordid>eNqNkV9LHDEUxYNU6qr9BlLy2JcZk0kmf3woFGlVECpSn0Mmc4fNMjPZJhlx_fTNstrH0qeQ3N_JPZyD0AUlNSVUXG7qHF5GyHVTbjWRNSHiCK2okrpiVOgPaEWYVBVvJD9BpyltSCG4aD-ik_LUUCnFCq0fIox-8rONO-zWNlqXIfpXm32YcRiwxdMS_Qx4Cj2MeAgR06qLYQrbGLa2DGZYYihevPN5d4Ufwwh7odvl4NYFBPzAW3KOjgc7Jvj0dp6hpx_ff13fVvc_b-6uv91XrpUqVx0hYK1QPRFWK9ky0F3H205wy3qlRM-45U43TA-y0ZxzOTAn2dBpOgBnDTtDXw7_Fnu_F0jZTD45GMdiNSzJUMXaVmpN-X-glGpC20YVlB9QF0NKEQazjX4qmRlKzL4OszGHOsy-DkOkKWEX2ee3DUs3Qf9X9J5_Ab4eACiRPHuIJjkPs4PeR3DZ9MH_e8MfMfOeAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811901528</pqid></control><display><type>article</type><title>Preliminary characterization of a murine model for 1-bromopropane neurotoxicity: Role of cytochrome P450</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Zong, Cai ; Garner, C. Edwin ; Huang, Chinyen ; Zhang, Xiao ; Zhang, Lingyi ; Chang, Jie ; Toyokuni, Shinya ; Ito, Hidenori ; Kato, Masashi ; Sakurai, Toshihiro ; Ichihara, Sahoko ; Ichihara, Gaku</creator><creatorcontrib>Zong, Cai ; Garner, C. Edwin ; Huang, Chinyen ; Zhang, Xiao ; Zhang, Lingyi ; Chang, Jie ; Toyokuni, Shinya ; Ito, Hidenori ; Kato, Masashi ; Sakurai, Toshihiro ; Ichihara, Sahoko ; Ichihara, Gaku</creatorcontrib><description>•Inhibition of P450s enabled mice to survive after 1-BP exposure at a lethal level.•Hepatotoxicity of 1-BP was significantly reduced by inhibition of P450s.•The present model is the first to show 1-BP-induced decrease in brain weight in mice.•The present model is the first to show 1-BP-induced increase in brain GRP78 in mice.•The present model is the first to show 1-BP-induced increase in brain Ran in mice.
Neurotoxicity of 1-bromopropane (1-BP) has been reported in both human cases and animal studies. To date, neurotoxicity of 1-BP has been induced in rats but not in mice due to the lethal hepatotoxicity of 1-BP. Oxidization by cytochromes P450 and conjugation with glutathione (GSH) are two critical metabolism pathways of 1-BP and play important roles in toxicity of 1-BP. The aim of the present study was to establish a murine model of 1-BP neurotoxicity, by reducing the hepatotoxicity of 1-BP with 1-aminobenzotriazole (1-ABT); a commonly used nonspecific P450s inhibitor. The results showed that subcutaneous or intraperitoneal injection of 1-ABT at 50mg/kg body weight BID (100mg/kg BW/day) for 3days, inhibited about 92–96% of hepatic microsomal CYP2E1 activity, but only inhibited about 62–64% of CYP2E1 activity in brain microsomes. Mice treated with 1-ABT survived even after exposure to 1200ppm 1-BP for 4 weeks and histopathological studies showed that treatment with 1-ABT protected mice from 1-BP-induced hepatic necrosis, hepatocyte degeneration, and hemorrhage. After 4-week exposure to 1-BP, the brain weight of 1-ABT(+)/1200ppm 1-BP group was decreased significantly. In 1-ABT-treated groups, expression of hippocampal Ran protein and cerebral cortical GRP78 was dose-dependently increased by exposure to 1-BP. We conclude that the control of hepatic P450 activity allows the observation of effects of 1-BP on the murine brain at a higher concentration by reduction of hepatotoxicity. The study suggests that further experiments with liver-specific control of P450 activity using gene technology might provide better murine models for 1-bromopropane-induced neurotoxicity.</description><identifier>ISSN: 0378-4274</identifier><identifier>EISSN: 1879-3169</identifier><identifier>DOI: 10.1016/j.toxlet.2016.07.006</identifier><identifier>PMID: 27421776</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>1-Aminobenzotriazole ; 1-Bromopropane ; Animals ; Atmosphere Exposure Chambers ; Brain ; Cerebral Cortex - drug effects ; Cerebral Cortex - metabolism ; Cerebral Cortex - pathology ; Chemical and Drug Induced Liver Injury - etiology ; Chemical and Drug Induced Liver Injury - metabolism ; Chemical and Drug Induced Liver Injury - mortality ; Chemical and Drug Induced Liver Injury - prevention & control ; Conjugation ; Cytochrome P-450 Enzyme Inhibitors - administration & dosage ; Cytochrome P-450 Enzyme Inhibitors - therapeutic use ; Cytochrome P-450 Enzyme System - metabolism ; Cytochromes P450 ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Exposure ; Glutathione ; Heat-Shock Proteins - agonists ; Heat-Shock Proteins - metabolism ; Hepatotoxicity ; Hydrocarbons, Brominated - administration & dosage ; Hydrocarbons, Brominated - toxicity ; Injections, Intraperitoneal ; Injections, Subcutaneous ; Liver - drug effects ; Liver - metabolism ; Liver - pathology ; Male ; Mice ; Mice, Inbred C57BL ; Murine model ; Nerve Tissue Proteins - agonists ; Nerve Tissue Proteins - metabolism ; Neurons - drug effects ; Neurons - metabolism ; Neurons - pathology ; Neurotoxicity ; Neurotoxicity Syndromes - etiology ; Neurotoxicity Syndromes - metabolism ; Neurotoxicity Syndromes - pathology ; Organ Size - drug effects ; P450 ; ran GTP-Binding Protein - agonists ; ran GTP-Binding Protein - metabolism ; Reduction ; Solvents - administration & dosage ; Solvents - toxicity ; Toxicity ; Triazoles - administration & dosage ; Triazoles - therapeutic use</subject><ispartof>Toxicology letters, 2016-09, Vol.258, p.249-258</ispartof><rights>2016 Elsevier Ireland Ltd</rights><rights>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c578t-b00eaa68d06a98753e9bb45b64a3d886d34a4c9239f7294447f3c73fb91fe4323</citedby><cites>FETCH-LOGICAL-c578t-b00eaa68d06a98753e9bb45b64a3d886d34a4c9239f7294447f3c73fb91fe4323</cites><orcidid>0000-0001-5707-5300</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.toxlet.2016.07.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27421776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zong, Cai</creatorcontrib><creatorcontrib>Garner, C. Edwin</creatorcontrib><creatorcontrib>Huang, Chinyen</creatorcontrib><creatorcontrib>Zhang, Xiao</creatorcontrib><creatorcontrib>Zhang, Lingyi</creatorcontrib><creatorcontrib>Chang, Jie</creatorcontrib><creatorcontrib>Toyokuni, Shinya</creatorcontrib><creatorcontrib>Ito, Hidenori</creatorcontrib><creatorcontrib>Kato, Masashi</creatorcontrib><creatorcontrib>Sakurai, Toshihiro</creatorcontrib><creatorcontrib>Ichihara, Sahoko</creatorcontrib><creatorcontrib>Ichihara, Gaku</creatorcontrib><title>Preliminary characterization of a murine model for 1-bromopropane neurotoxicity: Role of cytochrome P450</title><title>Toxicology letters</title><addtitle>Toxicol Lett</addtitle><description>•Inhibition of P450s enabled mice to survive after 1-BP exposure at a lethal level.•Hepatotoxicity of 1-BP was significantly reduced by inhibition of P450s.•The present model is the first to show 1-BP-induced decrease in brain weight in mice.•The present model is the first to show 1-BP-induced increase in brain GRP78 in mice.•The present model is the first to show 1-BP-induced increase in brain Ran in mice.
Neurotoxicity of 1-bromopropane (1-BP) has been reported in both human cases and animal studies. To date, neurotoxicity of 1-BP has been induced in rats but not in mice due to the lethal hepatotoxicity of 1-BP. Oxidization by cytochromes P450 and conjugation with glutathione (GSH) are two critical metabolism pathways of 1-BP and play important roles in toxicity of 1-BP. The aim of the present study was to establish a murine model of 1-BP neurotoxicity, by reducing the hepatotoxicity of 1-BP with 1-aminobenzotriazole (1-ABT); a commonly used nonspecific P450s inhibitor. The results showed that subcutaneous or intraperitoneal injection of 1-ABT at 50mg/kg body weight BID (100mg/kg BW/day) for 3days, inhibited about 92–96% of hepatic microsomal CYP2E1 activity, but only inhibited about 62–64% of CYP2E1 activity in brain microsomes. Mice treated with 1-ABT survived even after exposure to 1200ppm 1-BP for 4 weeks and histopathological studies showed that treatment with 1-ABT protected mice from 1-BP-induced hepatic necrosis, hepatocyte degeneration, and hemorrhage. After 4-week exposure to 1-BP, the brain weight of 1-ABT(+)/1200ppm 1-BP group was decreased significantly. In 1-ABT-treated groups, expression of hippocampal Ran protein and cerebral cortical GRP78 was dose-dependently increased by exposure to 1-BP. We conclude that the control of hepatic P450 activity allows the observation of effects of 1-BP on the murine brain at a higher concentration by reduction of hepatotoxicity. The study suggests that further experiments with liver-specific control of P450 activity using gene technology might provide better murine models for 1-bromopropane-induced neurotoxicity.</description><subject>1-Aminobenzotriazole</subject><subject>1-Bromopropane</subject><subject>Animals</subject><subject>Atmosphere Exposure Chambers</subject><subject>Brain</subject><subject>Cerebral Cortex - drug effects</subject><subject>Cerebral Cortex - metabolism</subject><subject>Cerebral Cortex - pathology</subject><subject>Chemical and Drug Induced Liver Injury - etiology</subject><subject>Chemical and Drug Induced Liver Injury - metabolism</subject><subject>Chemical and Drug Induced Liver Injury - mortality</subject><subject>Chemical and Drug Induced Liver Injury - prevention & control</subject><subject>Conjugation</subject><subject>Cytochrome P-450 Enzyme Inhibitors - administration & dosage</subject><subject>Cytochrome P-450 Enzyme Inhibitors - therapeutic use</subject><subject>Cytochrome P-450 Enzyme System - metabolism</subject><subject>Cytochromes P450</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Exposure</subject><subject>Glutathione</subject><subject>Heat-Shock Proteins - agonists</subject><subject>Heat-Shock Proteins - metabolism</subject><subject>Hepatotoxicity</subject><subject>Hydrocarbons, Brominated - administration & dosage</subject><subject>Hydrocarbons, Brominated - toxicity</subject><subject>Injections, Intraperitoneal</subject><subject>Injections, Subcutaneous</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Murine model</subject><subject>Nerve Tissue Proteins - agonists</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Neurons - pathology</subject><subject>Neurotoxicity</subject><subject>Neurotoxicity Syndromes - etiology</subject><subject>Neurotoxicity Syndromes - metabolism</subject><subject>Neurotoxicity Syndromes - pathology</subject><subject>Organ Size - drug effects</subject><subject>P450</subject><subject>ran GTP-Binding Protein - agonists</subject><subject>ran GTP-Binding Protein - metabolism</subject><subject>Reduction</subject><subject>Solvents - administration & dosage</subject><subject>Solvents - toxicity</subject><subject>Toxicity</subject><subject>Triazoles - administration & dosage</subject><subject>Triazoles - therapeutic use</subject><issn>0378-4274</issn><issn>1879-3169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV9LHDEUxYNU6qr9BlLy2JcZk0kmf3woFGlVECpSn0Mmc4fNMjPZJhlx_fTNstrH0qeQ3N_JPZyD0AUlNSVUXG7qHF5GyHVTbjWRNSHiCK2okrpiVOgPaEWYVBVvJD9BpyltSCG4aD-ik_LUUCnFCq0fIox-8rONO-zWNlqXIfpXm32YcRiwxdMS_Qx4Cj2MeAgR06qLYQrbGLa2DGZYYihevPN5d4Ufwwh7odvl4NYFBPzAW3KOjgc7Jvj0dp6hpx_ff13fVvc_b-6uv91XrpUqVx0hYK1QPRFWK9ky0F3H205wy3qlRM-45U43TA-y0ZxzOTAn2dBpOgBnDTtDXw7_Fnu_F0jZTD45GMdiNSzJUMXaVmpN-X-glGpC20YVlB9QF0NKEQazjX4qmRlKzL4OszGHOsy-DkOkKWEX2ee3DUs3Qf9X9J5_Ab4eACiRPHuIJjkPs4PeR3DZ9MH_e8MfMfOeAA</recordid><startdate>20160906</startdate><enddate>20160906</enddate><creator>Zong, Cai</creator><creator>Garner, C. Edwin</creator><creator>Huang, Chinyen</creator><creator>Zhang, Xiao</creator><creator>Zhang, Lingyi</creator><creator>Chang, Jie</creator><creator>Toyokuni, Shinya</creator><creator>Ito, Hidenori</creator><creator>Kato, Masashi</creator><creator>Sakurai, Toshihiro</creator><creator>Ichihara, Sahoko</creator><creator>Ichihara, Gaku</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>8FD</scope><scope>FR3</scope><scope>KR7</scope><orcidid>https://orcid.org/0000-0001-5707-5300</orcidid></search><sort><creationdate>20160906</creationdate><title>Preliminary characterization of a murine model for 1-bromopropane neurotoxicity: Role of cytochrome P450</title><author>Zong, Cai ; Garner, C. Edwin ; Huang, Chinyen ; Zhang, Xiao ; Zhang, Lingyi ; Chang, Jie ; Toyokuni, Shinya ; Ito, Hidenori ; Kato, Masashi ; Sakurai, Toshihiro ; Ichihara, Sahoko ; Ichihara, Gaku</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c578t-b00eaa68d06a98753e9bb45b64a3d886d34a4c9239f7294447f3c73fb91fe4323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>1-Aminobenzotriazole</topic><topic>1-Bromopropane</topic><topic>Animals</topic><topic>Atmosphere Exposure Chambers</topic><topic>Brain</topic><topic>Cerebral Cortex - drug effects</topic><topic>Cerebral Cortex - metabolism</topic><topic>Cerebral Cortex - pathology</topic><topic>Chemical and Drug Induced Liver Injury - etiology</topic><topic>Chemical and Drug Induced Liver Injury - metabolism</topic><topic>Chemical and Drug Induced Liver Injury - mortality</topic><topic>Chemical and Drug Induced Liver Injury - prevention & control</topic><topic>Conjugation</topic><topic>Cytochrome P-450 Enzyme Inhibitors - administration & dosage</topic><topic>Cytochrome P-450 Enzyme Inhibitors - therapeutic use</topic><topic>Cytochrome P-450 Enzyme System - metabolism</topic><topic>Cytochromes P450</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Exposure</topic><topic>Glutathione</topic><topic>Heat-Shock Proteins - agonists</topic><topic>Heat-Shock Proteins - metabolism</topic><topic>Hepatotoxicity</topic><topic>Hydrocarbons, Brominated - administration & dosage</topic><topic>Hydrocarbons, Brominated - toxicity</topic><topic>Injections, Intraperitoneal</topic><topic>Injections, Subcutaneous</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Murine model</topic><topic>Nerve Tissue Proteins - agonists</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Neurons - pathology</topic><topic>Neurotoxicity</topic><topic>Neurotoxicity Syndromes - etiology</topic><topic>Neurotoxicity Syndromes - metabolism</topic><topic>Neurotoxicity Syndromes - pathology</topic><topic>Organ Size - drug effects</topic><topic>P450</topic><topic>ran GTP-Binding Protein - agonists</topic><topic>ran GTP-Binding Protein - metabolism</topic><topic>Reduction</topic><topic>Solvents - administration & dosage</topic><topic>Solvents - toxicity</topic><topic>Toxicity</topic><topic>Triazoles - administration & dosage</topic><topic>Triazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zong, Cai</creatorcontrib><creatorcontrib>Garner, C. Edwin</creatorcontrib><creatorcontrib>Huang, Chinyen</creatorcontrib><creatorcontrib>Zhang, Xiao</creatorcontrib><creatorcontrib>Zhang, Lingyi</creatorcontrib><creatorcontrib>Chang, Jie</creatorcontrib><creatorcontrib>Toyokuni, Shinya</creatorcontrib><creatorcontrib>Ito, Hidenori</creatorcontrib><creatorcontrib>Kato, Masashi</creatorcontrib><creatorcontrib>Sakurai, Toshihiro</creatorcontrib><creatorcontrib>Ichihara, Sahoko</creatorcontrib><creatorcontrib>Ichihara, Gaku</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Civil Engineering Abstracts</collection><jtitle>Toxicology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zong, Cai</au><au>Garner, C. Edwin</au><au>Huang, Chinyen</au><au>Zhang, Xiao</au><au>Zhang, Lingyi</au><au>Chang, Jie</au><au>Toyokuni, Shinya</au><au>Ito, Hidenori</au><au>Kato, Masashi</au><au>Sakurai, Toshihiro</au><au>Ichihara, Sahoko</au><au>Ichihara, Gaku</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preliminary characterization of a murine model for 1-bromopropane neurotoxicity: Role of cytochrome P450</atitle><jtitle>Toxicology letters</jtitle><addtitle>Toxicol Lett</addtitle><date>2016-09-06</date><risdate>2016</risdate><volume>258</volume><spage>249</spage><epage>258</epage><pages>249-258</pages><issn>0378-4274</issn><eissn>1879-3169</eissn><abstract>•Inhibition of P450s enabled mice to survive after 1-BP exposure at a lethal level.•Hepatotoxicity of 1-BP was significantly reduced by inhibition of P450s.•The present model is the first to show 1-BP-induced decrease in brain weight in mice.•The present model is the first to show 1-BP-induced increase in brain GRP78 in mice.•The present model is the first to show 1-BP-induced increase in brain Ran in mice.
Neurotoxicity of 1-bromopropane (1-BP) has been reported in both human cases and animal studies. To date, neurotoxicity of 1-BP has been induced in rats but not in mice due to the lethal hepatotoxicity of 1-BP. Oxidization by cytochromes P450 and conjugation with glutathione (GSH) are two critical metabolism pathways of 1-BP and play important roles in toxicity of 1-BP. The aim of the present study was to establish a murine model of 1-BP neurotoxicity, by reducing the hepatotoxicity of 1-BP with 1-aminobenzotriazole (1-ABT); a commonly used nonspecific P450s inhibitor. The results showed that subcutaneous or intraperitoneal injection of 1-ABT at 50mg/kg body weight BID (100mg/kg BW/day) for 3days, inhibited about 92–96% of hepatic microsomal CYP2E1 activity, but only inhibited about 62–64% of CYP2E1 activity in brain microsomes. Mice treated with 1-ABT survived even after exposure to 1200ppm 1-BP for 4 weeks and histopathological studies showed that treatment with 1-ABT protected mice from 1-BP-induced hepatic necrosis, hepatocyte degeneration, and hemorrhage. After 4-week exposure to 1-BP, the brain weight of 1-ABT(+)/1200ppm 1-BP group was decreased significantly. In 1-ABT-treated groups, expression of hippocampal Ran protein and cerebral cortical GRP78 was dose-dependently increased by exposure to 1-BP. We conclude that the control of hepatic P450 activity allows the observation of effects of 1-BP on the murine brain at a higher concentration by reduction of hepatotoxicity. The study suggests that further experiments with liver-specific control of P450 activity using gene technology might provide better murine models for 1-bromopropane-induced neurotoxicity.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27421776</pmid><doi>10.1016/j.toxlet.2016.07.006</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-5707-5300</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-4274 |
ispartof | Toxicology letters, 2016-09, Vol.258, p.249-258 |
issn | 0378-4274 1879-3169 |
language | eng |
recordid | cdi_proquest_miscellaneous_1835579914 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | 1-Aminobenzotriazole 1-Bromopropane Animals Atmosphere Exposure Chambers Brain Cerebral Cortex - drug effects Cerebral Cortex - metabolism Cerebral Cortex - pathology Chemical and Drug Induced Liver Injury - etiology Chemical and Drug Induced Liver Injury - metabolism Chemical and Drug Induced Liver Injury - mortality Chemical and Drug Induced Liver Injury - prevention & control Conjugation Cytochrome P-450 Enzyme Inhibitors - administration & dosage Cytochrome P-450 Enzyme Inhibitors - therapeutic use Cytochrome P-450 Enzyme System - metabolism Cytochromes P450 Disease Models, Animal Dose-Response Relationship, Drug Exposure Glutathione Heat-Shock Proteins - agonists Heat-Shock Proteins - metabolism Hepatotoxicity Hydrocarbons, Brominated - administration & dosage Hydrocarbons, Brominated - toxicity Injections, Intraperitoneal Injections, Subcutaneous Liver - drug effects Liver - metabolism Liver - pathology Male Mice Mice, Inbred C57BL Murine model Nerve Tissue Proteins - agonists Nerve Tissue Proteins - metabolism Neurons - drug effects Neurons - metabolism Neurons - pathology Neurotoxicity Neurotoxicity Syndromes - etiology Neurotoxicity Syndromes - metabolism Neurotoxicity Syndromes - pathology Organ Size - drug effects P450 ran GTP-Binding Protein - agonists ran GTP-Binding Protein - metabolism Reduction Solvents - administration & dosage Solvents - toxicity Toxicity Triazoles - administration & dosage Triazoles - therapeutic use |
title | Preliminary characterization of a murine model for 1-bromopropane neurotoxicity: Role of cytochrome P450 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T07%3A46%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preliminary%20characterization%20of%20a%20murine%20model%20for%201-bromopropane%20neurotoxicity:%20Role%20of%20cytochrome%20P450&rft.jtitle=Toxicology%20letters&rft.au=Zong,%20Cai&rft.date=2016-09-06&rft.volume=258&rft.spage=249&rft.epage=258&rft.pages=249-258&rft.issn=0378-4274&rft.eissn=1879-3169&rft_id=info:doi/10.1016/j.toxlet.2016.07.006&rft_dat=%3Cproquest_cross%3E1835579914%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811901528&rft_id=info:pmid/27421776&rft_els_id=S0378427416322822&rfr_iscdi=true |